M
Motilal Oswal Sensex Healthcare ETF
MOHEALTH Share Price
42.84
-0.50 (-1.15%) 
Last Updated on 15 Jan 2025 at 10:19
Open at
43.34
52W High
46.97
52W Low
32.15
MOHEALTH Companies Weightage
Companies | LTP | Change%  | Weightage | Market Cap (Cr.) | PE Ratio | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|
 S Sun Pharmaceutical | 1,768.75 | 1.30% | 15.88% | 424886.2 | 37.9 | 1960.2 | 1290.7 |
 D Divis Laboratories | 5,997.85 | 4.64% | 5.94% | 159023.6 | 86.7 | 6448.75 | 3350.05 |
 C Cipla | 1,448.00 | 0.64% | 4.37% | 116922.3 | 25.3 | 1702 | 1268.4 |
 D Dr Reddys Laboratories | 1,337.30 | 0.24% | 4.17% | 111606.6 | 20.9 | 1420.2 | 1104.69 |
 T Torrent Pharmaceuticals | 3,254.35 | 0.48% | 4.11% | 110076 | 63.3 | 3589.95 | 2410.65 |
 M Mankind Pharma | 2,671.45 | 3.12% | 4.11% | 109984.1 | 52.1 | 3050 | 1910.1 |
 M Max Healthcare Institute | 1,086.85 | 0.41% | 3.94% | 105466.6 | 99.8 | 1227.5 | 695.4 |
 Z Zydus Life Science | 1,000.80 | 2.72% | 3.76% | 100638.5 | 23.5 | 1323.9 | 685.85 |
 L Lupin | 2,155.25 | 0.06% | 3.67% | 98292.3 | 37.4 | 2403.45 | 1367.45 |
 A Aurobindo Pharma | 1,174.90 | 1.12% | 2.55% | 68215.2 | 18.9 | 1592.55 | 959.05 |
 A Alkem Laboratories | 5,272.55 | 0.81% | 2.35% | 62948.6 | 29 | 6440 | 4409.9 |
 F Fortis Healthcare | 663.65 | 0.03% | 1.87% | 50095.2 | 72.4 | 744 | 375.1 |
 B Biocon | 387.70 | 6.28% | 1.74% | 46541.3 | 33.4 | 395.65 | 244.4 |
 G Glenmark Pharmaceuticals | 1,514.95 | 1.16% | 1.60% | 42778.3 | - | 1830.05 | 766.65 |
 I IPCA Laboratories | 1,588.30 | 0.54% | 1.51% | 40292 | 60 | 1757.65 | 1058.7 |
 S Syngene International | 828.25 | 0.60% | 1.24% | 33309.9 | 72.3 | 960 | 608 |
 P Piramal Pharma | 234.85 | 1.03% | 1.16% | 31148.5 | - | 307.85 | 114.45 |
 L Laurus Labs | 568.25 | 1.69% | 1.14% | 30624.2 | 233.9 | 619.5 | 358.7 |
 M Global Health | 1,031.80 | 0.31% | 1.04% | 27715.5 | 56.8 | 1513.75 | 936.05 |
 S Suven Pharmaceuticals | 1,054.75 | 0.46% | 1.00% | 26857.9 | 110.4 | 1359 | 586.1 |
 N Narayana Hrudayalaya | 1,291.55 | 1.61% | 0.99% | 26404.4 | 33.9 | 1445.05 | 1087.8 |
 A Aster DM Healthcare | 500.15 | 1.92% | 0.93% | 24965.7 | 110.4 | 558.3 | 312.25 |
 K Krishna Institute of Medical Sciences | 618.95 | 0.05% | 0.93% | 24774.6 | 74.8 | 674 | 350.02 |
 C Concord Biotech | 2,329.30 | 2.89% | 0.91% | 24348.4 | 74.3 | 2658 | 1326.9 |
 N Natco Pharma | 1,255.80 | 3.58% | 0.84% | 22508.7 | 11.6 | 1638.35 | 804.7 |
 W Wockhardt | 1,367.60 | 3.73% | 0.83% | 22210 | - | 1580 | 402.85 |
 A Alembic Pharmaceuticals | 1,009.15 | 0.61% | 0.74% | 19843 | 31.1 | 1296.15 | 824.5 |
 C Caplin Point Laboratories | 2,334.05 | 3.26% | 0.66% | 17737.3 | 36 | 2636 | 1221 |
 E Eris Lifesciences | 1,278.45 | 2.44% | 0.65% | 17399.4 | 49.9 | 1593 | 810.1 |
 N Neuland Laboratories | 13,289.05 | 1.50% | 0.64% | 17065.9 | 64.6 | 18089.55 | 5390 |
 J Jubilant Pharmova | 962.20 | 4.05% | 0.57% | 15327.6 | 53.1 | 1309 | 532.05 |
 I Indegene | 632.65 | 4.86% | 0.57% | 15139.7 | 40.8 | 736.6 | 468.9 |
 G Granules | 584.45 | 2.99% | 0.53% | 14155.6 | 29.1 | 724.55 | 382.05 |
 G Glenmark Life Sciences | 1,020.80 | 3.69% | 0.47% | 12484.9 | 29.5 | 1335 | 666.05 |
 M Marksans Pharma | 257.90 | 3.80% | 0.44% | 11690.3 | 33.7 | 358.5 | 126.05 |
 J Jupiter Life Line Hospital | 1,558.10 | 0.58% | 0.38% | 10161.7 | 55.7 | 1649.95 | 1037.4 |
 B Blue Jet Healthcare | 581.60 | 2.14% | 0.38% | 10085.3 | 57.7 | 618.3 | 324.45 |
 P Procter & Gamble Health | 5,316.10 | 2.36% | 0.33% | 8882.5 | 38.9 | 5835.95 | 4640.3 |
 A Ami Organics | 2,030.35 | 2.67% | 0.31% | 8296.4 | 89 | 2395.85 | 1005.05 |
 F Fairdeal Corporation | 481.30 | 1.58% | 0.29% | 7832.8 | 24.8 | 659 | 402.55 |
 S Shilpa Medicare | 779.85 | 6.49% | 0.28% | 7618.9 | 132.9 | 959.95 | 316.55 |
 H Healthcare Global Enterprises | 498.60 | 1.85% | 0.26% | 6963.9 | 128.2 | 553.25 | 310.1 |
 K Kovai Medical Center Hospital | 5,794.15 | 5.62% | 0.24% | 6338.8 | 31.4 | 6400 | 3150 |
 I Innova Captab | 1,040.50 | 2.38% | 0.22% | 5942.8 | 50.3 | 1259 | 421.55 |
 S Sun Pharma Advanced Research Co | 179.95 | 3.09% | 0.22% | 5838.1 | - | 474 | 170.75 |
 S Strides Pharma Science | 624.95 | 0.95% | 0.22% | 5755.1 | 28 | 785.85 | 282.42 |
 U Unichem Laboratories | 685.50 | 1.37% | 0.18% | 4833 | 96.4 | 949.85 | 433.25 |
 H Hikal | 365.95 | 5.28% | 0.17% | 4488.8 | 61.4 | 464.5 | 260.65 |
 S Sequent Scientific | 179.05 | 4.83% | 0.17% | 4477.7 | 229.6 | 240.9 | 91.85 |
 T Thyrocare Technologies | 825.30 | 0.22% | 0.16% | 4375.3 | 52.1 | 1053.05 | 555.85 |
 I Indraprastha Medical Corporation | 476.80 | 4.14% | 0.16% | 4368.7 | 29.6 | 571.95 | 155.55 |
 D Dishman Carbogen Amcis | 260.00 | 2.10% | 0.15% | 4074.8 | - | 307.8 | 132.75 |
 A Advanced Enzyme Tech | 344.55 | 2.77% | 0.14% | 3840.9 | 26.2 | 571.15 | 332 |
 M Morepen Laboratories | 67.92 | 4.65% | 0.14% | 3722.2 | 28.3 | 100.8 | 38.56 |
 R RPG Life Sciences | 2,055.15 | 2.56% | 0.13% | 3403.2 | 39 | 2976.7 | 1363.9 |
 G Gujarat Themis Biosyn | 311.95 | 4.31% | 0.13% | 3399.2 | 64.4 | 390 | 189.37 |
 A Ajanta Pharma | 2,814.85 | 1.12% | 0.12% | 3339.9 | 40.2 | 3485.75 | 2003.55 |
 I Indoco Remedies | 325.35 | 0.53% | 0.11% | 2996.4 | 122.3 | 414.35 | 286.5 |
 K Krsnaa Diagnostics | 865.40 | 4.23% | 0.10% | 2791 | 40.4 | 1041.8 | 527.55 |
 S Shalby Hospitals | 222.30 | 3.90% | 0.09% | 2390.7 | 43.8 | 333.85 | 204.5 |
 S Solara Active Pharma Sciences | 662.95 | 4.69% | 0.09% | 2383.7 | - | 885.95 | 321.93 |
 I IOL Chemicals & Pharmaceuticals | 395.05 | 4.33% | 0.09% | 2318.3 | 23.2 | 537.05 | 333 |
 T Themis Medicare | 250.40 | 1.38% | 0.09% | 2306.5 | 43.5 | 313.65 | 182.45 |
 N Novartis | 852.30 | 1.84% | 0.08% | 2104.4 | 24.1 | 1248 | 805 |
 T Tarsons Products | 394.50 | 1.31% | 0.08% | 2103.5 | 49.2 | 543.8 | 377.75 |
 W Windlas Biotech | 986.65 | 6.73% | 0.08% | 2058.7 | 33.7 | 1197 | 452.65 |
 H Hester Biosciences | 2,233.80 | 1.27% | 0.07% | 1895.3 | 81 | 3375.45 | 1292.9 |
 S SMS Pharmaceuticals | 222.20 | 2.73% | 0.07% | 1871.3 | 31.7 | 398 | 119.8 |
 B Bliss GVS Pharma | 163.70 | 3.94% | 0.06% | 1724.2 | 20.5 | 184.95 | 92.25 |
 S Syncom Formulations | 18.22 | 5.99% | 0.06% | 1708.9 | 52.1 | 27.94 | 11 |
 L Lincoln Pharmaceuticals | 789.95 | 2.86% | 0.06% | 1584.1 | 16.4 | 975 | 498 |
 S Sigachi Industries | 46.25 | 2.32% | 0.06% | 1543.2 | 23.4 | 95.94 | 43.42 |
 G GPT Healthcare | 173.20 | 3.56% | 0.05% | 1418.1 | 34.1 | 219.7 | 129 |
 K KMC Speciality Hospitals | 74.21 | 0.15% | 0.05% | 1210.4 | 46.7 | 104.95 | 69 |
 N NGL Fine Chem | 1,702.15 | 2.59% | 0.04% | 1041.2 | 25.4 | 2822.5 | 1631.7 |
 K Kopran | 199.30 | 4.98% | 0.04% | 960.4 | 18.2 | 369.2 | 187 |
 S Sastasundar Ventures | 288.85 | 0.80% | 0.03% | 919 | 7.3 | 455 | 270 |
Invest in MOHEALTH
Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
error
Or Scan the QR Code to download the Dhan App
Join us on
Follow us on
Partner with us
built with love
for Indians who love to invest & trade
We are part of Raise Financial Services
Explore | Sitemap
*All securities mentioned on this website are exemplary and not recommendatory.
We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.
Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.
That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.
©2021-2025 Moneylicious Securities Private Limited. All rights reserved. CIN: U74999MH2012PTC433549 Moneylicious Securities is part of Raise Financial Services.
SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India.
Corporate Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India. Customer Care: 9987761000.
For any query / feedback / clarifications, email at help@dhan.co.
Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details
Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Saarthi 2.0 Mobile App for Investors
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India.
Corporate Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India. Customer Care: 9987761000.
Details of client bank account
For any query / feedback / clarifications, email at help@dhan.co.
In case of grievances for any of the services rendered by Moneylicious Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.
Disclaimer: All communications with the client in the chat section are for support purposes only, and any commitments or statements made by the agent (human or virtual) shall not be binding on the company.
DHAN is a brand owned by Moneylicious Securities Private Limited. All DHAN clients are registered under Moneylicious Securities Private Limited. Clients are advised to refer to our company as Moneylicious Securities Private Limited when communicating with regulatory authorities.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances
Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit
Attention investors:
- Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
- Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
- Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.
Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / Moneylicious / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.
Moneylicious Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/
Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX
Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets
Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details
Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Saarthi 2.0 Mobile App for Investors